Mosaic ImmunoEngineering (OTCMKTS:CPMV) Trading Down 32.6% – Should You Sell?

Posted by Tyrone Williams on Feb 21st, 2026

Shares of Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV – Get Free Report) dropped 32.6% on Thursday . The company traded as low as $0.3571 and last traded at $0.3571. Approximately 104 shares were traded during mid-day trading, a decline of 75% from the average daily volume of 408 shares. The stock had previously closed at $0.5295.

Mosaic ImmunoEngineering Price Performance

The stock has a fifty day moving average of $0.48 and a 200 day moving average of $0.57. The stock has a market cap of $2.59 million, a price-to-earnings ratio of -3.97 and a beta of -0.76.

Mosaic ImmunoEngineering (OTCMKTS:CPMV – Get Free Report) last posted its quarterly earnings results on Wednesday, November 19th. The company reported ($0.02) earnings per share (EPS) for the quarter.

About Mosaic ImmunoEngineering

(Get Free Report)

Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.

Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.